Raul Mendez

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/622577/raul-mendez-publications-by-year.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43 707 16 26 g-index

50 1,062 5 4.12 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
43	Ceftobiprole medocaril <i>Revista Espanola De Quimioterapia</i> , 2022 , 35 Suppl 1, 25-27	1.6	O
42	Factors associated with one-year mortality in hospitalised patients with exacerbated bronchiectasis. <i>Archivos De Bronconeumologia</i> , 2022 ,	0.7	2
41	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 41, 271	5.3	
40	Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. <i>Journal of Internal Medicine</i> , 2021 , 290, 621-631	10.8	52
39	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1075-1085	11.6	3
38	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1087-1097	4.7	3
37	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. <i>Haematologica</i> , 2021 , 106, 1636-1646	6.6	15
36	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 257-265	4.7	4
35	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2021 ,	1.6	5
34	Reduced Diffusion Capacity in COVID-19 Survivors. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1253-1255	4.7	18
33	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2021 , 1	5.8	3
32	Long-term neuropsychiatric outcomes in COVID-19 survivors: A 1-year longitudinal study. <i>Journal of Internal Medicine</i> , 2021 ,	10.8	7
31	Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. <i>Critical Care</i> , 2020 , 24, 691	10.8	99
30	Reply to D ual antibiotic therapy for outpatient management of community-acquired pneumonia? <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
29	Reply to "Dual Antibiotic Therapy for Outpatient Management of Community-Acquired Pneumonia?". <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
28	Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
27	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020 , 80, e23-e24	18.9	62

(2017-2020)

Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections 26 2020, 212-228 Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. 25 Archivos De Bronconeumologia, 2020, 56, 551-558 Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. 24 0.7 1 Archivos De Bronconeumologia, 2020, 56, 551-558 Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of. Journal of Clinical 23 5.1 10 Medicine, **2020**, 9, Neumon adquirida en la comunidad. Normativa de la Sociedad Espa la de Neumolog y Cirug B 22 0.7 11 Tordica (SEPAR). Actualizacili 2020. Archivos De Bronconeumologia, 2020, 56, 1-10 Simultaneous Depression of Immunological Synapse and Endothelial Injury is Associated with 21 5.1 10 Organ Dysfunction in Community-Acquired Pneumonia. Journal of Clinical Medicine, 2019, 8, Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events 20 21 5.3 Are Identified by Cardiac Biomarkers. Chest, 2019, 156, 1080-1091 Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. Journal of Clinical 19 5.1 Medicine, 2019, 8, Soluble P-Selectin in Acute Exacerbations and Stable Bronchiectasis in Adults. Annals of the 18 2 4.7 American Thoracic Society, 2019, 16, 1587-1591 Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response 18.9 28 17 and increased severity and mortality. Journal of Infection, 2019, 78, 423-431 Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with 16 5.1 1 Exacerbations of Bronchiectasis: A Prospective Cohort Study. Journal of Clinical Medicine, 2019, 8, Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of 15 10.2 Symptoms. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 370-378 Bronchiectasis and Multidrug-resistant Microorganisms: The Ideal Niche?. Archivos De 14 0.7 Bronconeumologia, 2018, 54, 543-544 New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. American Journal of Respiratory and Critical Care Medicine, 2017, 13 10.2 103 196, 1287-1297 Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. 12 7.3 19 Respiratory Research, 2017, 18, 176 Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated 8.8 11 43 with Higher Risk of Mortality. EBioMedicine, 2017, 24, 231-236 Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. BMC Infectious 10 4 17 Diseases, 2017, 17, 659 Solithromycin: the future of macrolide is now. Annals of Research Hospitals, 2017, 1, 1-1 1.6 9

8	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017 , 35, 5264-5270	4.1	17
7	Age-related risk factors for bacterial aetiology in community-acquired pneumonia. <i>Respirology</i> , 2016 , 21, 1472-1479	3.6	16
6	Non-cystic fibrosis bronchiectasis: The long road to multidrug resistant bacteria. <i>Community Acquired Infection</i> , 2016 , 3, 110	О	2
5	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0145929	3.7	44
4	ESICM LIVES 2016: part one. Intensive Care Medicine Experimental, 2016, 4,	3.7	5
3	Lung inflammatory pattern and antibiotic treatment in pneumonia. Respiratory Research, 2015, 16, 15	7-3	24
2	Lung inflammatory pattern and antibiotic treatment in pneumonia. <i>Respiratory Research</i> , 2015 , 16, 15 C-Reactive Protein at Discharge, Diabetes Mellitus and [I] Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 306-14	7.3	24 17